News

November 9, 2016November 9, 2016

Breast Cancer Treatment, Tamoxifen, Seen to Block Mesothelioma in Early Study

News

Tamoxifen, a medication that blocks the effects of estrogen, worked to prevent the growth of malignant pleural mesothelioma cells cultured in the lab, and to improve the cells’ sensitivity to chemotherapy. Interestingly, ... Read more

November 8, 2016

Epizyme Updates Clinical Trial Data on Tazemotostat for Mesothelioma, Other Cancers

News

Epizyme has reported recent updates from its clinical-stage programs with the company’s lead candidate, tazemotostat, for the treatment of hematological malignancies and genetically defined solid tumors. Tazemotostat, a first-in-class small molecule, oral ... Read more

November 7, 2016November 7, 2016

Preclinical Study Supports Platinum Treatment, Ptac2S, as Promising MPM Therapy

News

The experimental anti-cancer platinum drug Ptac2S has higher anti-cancer activity than standard of care cisplatin in malignant pleural mesothelioma (MPM) cells, researchers reported, a preclinical finding that suggests it may be a ... Read more

November 4, 2016

McCulloch Appointed to Pacific Mesothelioma Center Board of Directors

News

Alexa McCulloch has been appointed treasurer on the board of directors of the Pacific Mesothelioma Center (PMC), a division of the Pacific Heart, Lung & Blood Institute (PHLBI). McCulloch has held numerous ... Read more

November 3, 2016

£5 Million Donation Will Help Establish UK Mesothelioma Research Center

News

The British Lung Foundation has just announced a donation of £5 million British pounds (about $6.23 million U.S.) from the Victor Dahdaleh Foundation, matching government funding that was announced earlier ... Read more

November 2, 2016November 2, 2016

Targovax Reports Promising Early Data on Vaccine Now in Mesothelioma Clinical Trial

News

Targovax recently presented preclinical and clinical results of the anti-tumor efficacy of its cancer vaccine ONCOS-102 for the treatment of malignant mesothelioma. The presentation, “OR52: Anti-tumor potency of cancer vaccine ... Read more

November 1, 2016

Enhancer Seen to Work Well with Mesothelioma Therapy Now in Clinical Trial

News

SVP-Rapamycin, an immunotherapy developed by Selecta Biosciences, can strengthen the effective of an anti-mesothelioma therapy, according to preclinical data recently presented at the Immunogenicity and Bioassay Summit 2016 in Baltimore. These findings ... Read more

October 31, 2016October 31, 2016

FDA Pauses Enrollment in Trials Testing Listeria as Therapy for Mesothelioma and Other Cancers

News

The U.S. Food and Drug Administration (FDA) has placed a partial hold on all clinical trials evaluating the LADD (Listeria-based immunotherapy construct) technology platform, pausing new patient enrollment. Those already undergoing therapy will ... Read more

October 28, 2016October 28, 2016

Potential Biomarker of Pleural Mesothelioma Fails to Distinguish Disease from Lung Cancers in Study

News

A protein known as CD90, which has been suggested as a possible biomarker for malignant pleural mesothelioma (MM), may not contribute to the reliable diagnosis of this disease after all, ... Read more

October 27, 2016

GSK Investigational Drug Prevents Mesothelioma Growth in Mice, Supporting Human Trials

News

A GlaxoSmithKline experimental drug, GSK3052230, prevents tumor growth in mice carrying human mesothelioma tumors. The data supports ongoing investigations of the drug as a mesothelioma treatment. The study, “Inhibition of FGF/FGFR autocrine signaling ... Read more